【摘要】 本研究用重组白细胞介素２（ｒＩＬ－２）联合转移因子（ＴＦ）或抗肿瘤免疫核糖核酸（ｉＲＮＡ）作用于外周血单个核细胞（ＰＢＭＣ），测定其对Ｋ５６２，Ｒａｊｉ及Ｈ７４０４细胞的杀伤活性。结果发现，高浓度ＴＦ（０．２５ｕ／ｍｌ）可抑制ＬＡＫ活性，ＴＦ进一步稀释（０．１２５ｕ／ｍｌ）可使其抑制作用消失。ＴＦ和抗肿瘤ｉＲＮＡ不能进一步提高最适剂量ｒＩＬ－２（５００ｕ／ｍｌ）诱导的ＬＡＫ活性，但能显著增强亚适剂量ｒＩＬ－２（２００ｕ／ｍｌ）诱导的ＬＡＫ活性，诱导ＬＡＫ活性增高的ＴＦ最适剂量为０．０３１ｕ／ｍｌ。ＴＦ或抗肿瘤ｉＲＮＡ单独不能诱导出ＬＡＫ活性，而当两者联合应用可诱导ＰＢＭＣ产生ＬＡＫ活性。本文为ＴＦ及抗肿瘤ｉＲＮＡ协同ＬＡＫ细胞疗法在临床应用提供实验基础。更多还原

【Abstract】 Lymphokine-activated killer (LAK) cell activity was measured in human peripheral blood mononuclear cell (PBMC) treated in vitro for 5 days with recombinant interleukine-2(rIL-2) and transfer factor or antitumor immune RNA. Lytic activity was measured utilizing K562 (NK-sensitive),Raji (NK-resistant) and H7404 (NK-resistant) target cells. LAK cell activity was inhibited by high concentration of TF (0. 25U/ml), while not affected by lower concentration of TF(0. 125U/ml).The combination of TF or antitumor iRNA with suboptimal concentration of rIL-2(200U/ml) showed enhancement of LAK cell activity,while TF and antitumor iRNA could not increase LAK cell activity induced by rIL-2 at optimal concentration (500U/ml)and at low concentration (10U/ml). PBMC cultured respectively with TF or antitumor iRNA could not lyse Ran and H7404.When they were cultured both with TF and antitumor iRNA without rIL-2,LAK activity could be induced. These results laid the experiment basis for the usage of TF and antitumor iRNA combining with LAK therapy in clinic.更多还原